Prognostic classification of endometrial cancer using a molecular approach based on a twelve-gene NGS panel.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
02 12 2019
Historique:
received: 17 06 2019
accepted: 18 11 2019
entrez: 4 12 2019
pubmed: 4 12 2019
medline: 11 11 2020
Statut: epublish

Résumé

Endometrial Cancer (EC) is one of the most common malignancies in women in developed countries. Molecular characterization of different biotypes may improve clinical management of EC. The Cancer Genome Atlas (TCGA) project has revealed four prognostic EC subgroups: POLE, MSI; Copy Number Low (CNL) and Copy Number High (CNH). The goal of this study was to develop a method to classify tumors in any of the four EC prognostic groups using affordable molecular techniques. Ninety-six Formalin-Fixed Paraffin-embedded (FFPE) samples were sequenced following a NGS TruSeq Custom Amplicon low input (Illumina) protocol interrogating a multi-gene panel. MSI analysis was performed by fragment analysis using eight specific microsatellite markers. A Random Forest classification algorithm (RFA), considering NGS results, was developed to stratify EC patients into different prognostic groups. Our approach correctly classifies the EC patients into the four TCGA prognostic biotypes. The RFA assigned the samples to the CNH and CNL groups with an accuracy of 0.9753 (p < 0.001). The prognostic value of these groups was prospectively reproduced on our series both for Disease-Free Survival (p = 0.004) and Overall Survival (p = 0.030).Hence, with the molecular approach herein described, a precise and suitable tool that mimics the prognostic EC subtypes has been solved and validated. Procedure that might be introduced into routine diagnostic practices.

Identifiants

pubmed: 31792358
doi: 10.1038/s41598-019-54624-x
pii: 10.1038/s41598-019-54624-x
pmc: PMC6889294
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

18093

Références

Cancer. 2017 Mar 1;123(5):802-813
pubmed: 28061006
Clin Lab. 2017 Apr 1;63(4):705-716
pubmed: 28397474
Cancer. 2000 Feb 15;88(4):814-24
pubmed: 10679651
Gynecol Oncol Res Pract. 2016 Dec 13;3:14
pubmed: 27999680
Mod Pathol. 2015 Jun;28(6):836-44
pubmed: 25720322
Surg Oncol. 2016 Dec;25(4):370-377
pubmed: 27916168
Clin Cancer Res. 2016 Aug 15;22(16):4215-24
pubmed: 27006490
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Cancer. 2015 Feb 1;121(3):386-94
pubmed: 25224212
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Hematol Oncol Clin North Am. 2012 Feb;26(1):1-12
pubmed: 22244658
Int J Clin Exp Pathol. 2009;2(5):411-32
pubmed: 19294001
Obstet Gynecol Int. 2010;2010:984013
pubmed: 20396392
Gynecol Oncol. 2016 Oct;143(1):46-53
pubmed: 27421752
J Clin Pathol. 2010 May;63(5):410-5
pubmed: 20418232
Am J Surg Pathol. 2013 Jun;37(6):874-81
pubmed: 23629444
Virchows Arch. 2004 Mar;444(3):213-23
pubmed: 14747944
Genomics. 2012 Jun;99(6):323-9
pubmed: 22546560
Gynecol Oncol. 2016 Jan;140(1):6-7
pubmed: 26657841
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Gynecol Oncol. 2002 Dec;87(3):243-6
pubmed: 12468320
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-43
pubmed: 17161155
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427

Auteurs

Raquel López-Reig (R)

Laboratory of Molecular Biology, Services of Fundación Instituto Valenciano de Oncología, Valencia, Spain.

Antonio Fernández-Serra (A)

Laboratory of Molecular Biology, Services of Fundación Instituto Valenciano de Oncología, Valencia, Spain.

Ignacio Romero (I)

Medical Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.

Cristina Zorrero (C)

Gynecology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.

Carmen Illueca (C)

Pathology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.

Zaida García-Casado (Z)

Laboratory of Molecular Biology, Services of Fundación Instituto Valenciano de Oncología, Valencia, Spain.

Andrés Poveda (A)

Department of Oncology, INITIA ONCOLOGY, Hospital Quirón Salud, Valencia, Spain.

José Antonio López-Guerrero (JA)

Laboratory of Molecular Biology, Services of Fundación Instituto Valenciano de Oncología, Valencia, Spain. jalopez@fivo.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH